Case report: Intrapleural plus systemic Tislelizumab injection combined chemotherapy in RET gene fusion-positive lung adenocarcinoma presenting refractory malignant pleural effusion

RET fusions were discovered in non-small cell lung cancer (NSCLC), and the efficacy of RET-targeted treatment in these patients has been previously established. However, patients with required resistance to RET-TKIs have limited treatment options. Herein, we describe a case of critical and advanced...

Descripció completa

Dades bibliogràfiques

Autors principals:	Dong Qiu, Xiao-Hui Zhang, Yang Wang, Cheng Chen
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-09-01
Col·lecció:	Frontiers in Oncology
Matèries:	intrapleural immunotherapy immunotherapy RET gene fusion lung adenocarcinoma malignant pleural effusion
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1404173/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!